| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Aspects cliniques : Cancers HER2 et atteinte du système nerveux central, que faire en 2021 ?: Central nervous system metastases from HER2 positive breast cancers: what to do in 2021? |
| Creator | Bachelot et al. |
| Author | Thomas Bachelot |
| Author | Caroline Bailleux |
| Author | Amélie Darlix |
| Author | William Jacot |
| Abstract | Metastatic breast cancer is the second most common cause of brain metastasis (BM), and this problem is particularly marked for the amplified HER2 subtype (HER2+), with a cumulative incidence reaching up to 49 % in the ER-/HER2+ subgroup. Literature review shows that therapeutic progress has been major since the marketing of systemic anti-HER2+ treatments, with life expectancies now relatively unaffected by brain development. The recommended treatments are, on the one hand, specific treatment for brain development and, on the other hand, appropriate systemic treatment. Regarding local treatments, we will always favor surgery when possible, especially for large metastases, and stereotaxic radiotherapy, possibly iterative. One should be wary of whole brain irradiation which has never been shown to improve overall survival, but which is clearly associated with more cognitive toxicities. All the systemic anti-HER2 treatments currently on the market have shown efficacy on BM from HER2+ breast cancer and must therefore be chosen above all on the basis of their potential activity on the systemic disease at the time of cerebral evolution. If BM evolution happen without concomitant systemic progression, and local treatment can control it, it is not recommended to change the current medical treatment. Finally, randomized clinical studies opened to patients with active brain disease are starting to be published. The first of them showed the benefit of the triple combination tucatinib-trastuzumab-capecitabine in this context. |
| Publication | Bulletin Du Cancer |
| Volume | 108 |
| Issue | 11S |
| Pages | 11S26-11S34 |
| Date | 2021-12 |
| Journal Abbr | Bull Cancer |
| Language | fre |
| DOI | 10.1016/S0007-4551(21)00634-2 |
| ISSN | 1769-6917 |
| Short Title | Aspects cliniques |
| Library Catalog | PubMed |
| Extra | PMID: 34969513 |
| Tags | Aged, Antineoplastic Combined Chemotherapy Protocols, Blood-Brain Barrier, Brain metastases, Brain Neoplasms, Breast Neoplasms, Cancer du sein, Capecitabine, corresponding, Cranial Irradiation, Disease Progression, Female, first-last-corresponding, HER2 over-expression, HER2-positif, Humans, Lapatinib, last, Life Expectancy, Magnetic Resonance Imaging, marque, Metastasectomy, Métastases cérébrales, Middle Aged, Oxazoles, Pyridines, Quinazolines, Quinolines, Radiosurgery, Receptor, ErbB-2, Receptors, Estrogen, review, Stratégie, thérapeutique, Trastuzumab, Treatment strategy |
| Date Added | 2022/07/29 - 11:56:06 |
| Date Modified | 2022/08/01 - 16:18:58 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
